|本期目录/Table of Contents|

[1]刘晓楠,卓姗姗,岳玖玲,等.新辅助化疗在局部晚期口腔癌中的疗效分析[J].天津医科大学学报,2015,21(05):408-411.
　LIU Xiao-nan,ZHUO Shan-shan,YUE Jiu-ling,et al.Clinical curative effect on neoadjuvant chemotherapy in locally advanced oral cavity cancers[J].Journal of Tianjin Medical University,2015,21(05):408-411.
点击复制

新辅助化疗在局部晚期口腔癌中的疗效分析(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
21卷
期数:
2015年05期
页码:
408-411
栏目:
临床医学
出版日期:
2015-09-20

文章信息/Info

Title:
Clinical curative effect on neoadjuvant chemotherapy in locally advanced oral cavity cancers
文章编号:
1006-8147(2015)05-0408-04
作者:
刘晓楠; 卓姗姗; 岳玖玲; 张文超; 张 仑
(天津医科大学肿瘤医院颌面耳鼻喉肿瘤科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津,300060)
Author(s):
LIU Xiao-nan;  ZHUO Shan-shan; YUE Jiu-ling;  ZHANG Wen-chao; ZHANG Lun
(Department of Maxillofacial Ear,nose and Throat Oncology,Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin, 300060China)
关键词:
局部晚期口腔癌; 新辅助化疗; 手术治疗; 可切除率; 预后
Keywords:
locally advanced oral cavity cancers;  neoadjuvant chemotherapy;  surgery ;  resection?rate ; prognosis
分类号:
R739.8
DOI:
-
文献标志码:
A
摘要:
目的：探讨新辅助化疗在局部晚期口腔鳞癌中的疗效，分析影响局部晚期口腔癌预后的危险因素。方法：收集行新辅助化疗的局部晚期口腔癌患者的临床病理资料，并对预后影响因素行相关性分析。结果：新辅助化疗有效率为64.8%，完全缓解率为5.6%，部分缓解率为59.2%；肿瘤T分期降低者83例，降低2期者25例，降低1期者58例。患者的中位生存期为29个月，可手术组30个月，不可手术组21个月。多因素分析显示淋巴结转移、手术治疗、游离皮瓣修复、手术切缘为局部口腔癌预后影响因素。结论：新辅助化疗降低局部晚期口腔癌的分期，提高手术率，使患者生存获益。淋巴结转移、手术治疗、游离皮瓣修复、手术切缘是预后的独立危险因素。
Abstract:

Objective ：To explore the effects of neoadjuvant chemotherapy followed by surgery on locally advanced oral cavity cancers and to analyse the prognosis factors. Methods： Clinical pathologic features of patients with locally advanced oral cavity cancers, who were treated with neoadjuvant chemotherapy（NACT）were observed and the prognosis factors were analysed. Results： The response rate of NACT was 64.8%, and the complete response rate (CR)was 5.6%, and the partial response rate (PR)was 59.2%. The conditions of 83 cases at T stage were improved, 25 of which were improved for 2 stages while 58 improved for one stage. The median of estimated OS in patients undergoing surgery was 30 months and 21 months in patients treated without surgery. Regional lymph node metastasis, flap application, resection margin, surgery are identified as independent factors that influence prognosis. Conclusion：NACT could lead to successful resection and improve overall survival in locally advanced head and neck cancers followed by surgery. Regional lymph node metastasis, flap application, resection margin，surgery are independent risk factors of prognosis.

参考文献/References:

[1] 李志勇，张艳清，郑艳群，等.局部或区域晚期头颈鳞癌放化疗联合治疗现状和展望. [J]. 中华临床医师杂志(电子版),2013,7(22):10227
[2] Patil V M, Noronha V, Joshi A, et al. Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference[J]. Indian J Cancer, 2013,50(1):1
[3] 郑家伟，李金忠，涂文勇，等. 口腔颌面部恶性肿瘤治疗指南[J]. 中国口腔颌面外科杂志, 2010(02):98
[4] Liao C T, Chang J T, Wang H M, et al. Surgical outcome of T4a and resected T4b oral cavity cancer[J]. Cancer, 2006,107(2):337
[5] Crombie A K, Farah C, Tripcony L, et al. Primary chemoradiotherapy for oral cavity squamous cell carcinoma[J]. Oral Oncol, 2012,48(10):1014
[6] Patil V M, Prabhash K, Noronha V, et al. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers[J]. Oral Oncol, 2014,50(10):1000
[7] de Vicente J C, Rodriguez-Santamarta T, Rosado P, et al. Survival after free flap reconstruction in patients with advanced oral squamous cell carcinoma[J]. J Oral Maxillofac Surg, 2012,70(2):453
[8] Vermorken J B, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007,357(17):1695
[9] Posner M R, Hershock D M, Blajman C R, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J]. N Engl J Med, 2007,357(17):1705
[10]徐义全，李超，樊晋川，等. 两种新辅助化疗方案在头颈鳞癌综合治疗的临床研究[J]. 中华临床医师杂志(电子版), 2012，6(2):445
[11]吴文澜，张园. 多西他赛、顺铂和5-Fu新辅助化疗在中晚期或复发性头颈部鳞癌综合治疗中的应用[Z]. 国际暨全国头颈肿瘤学术大会论文集，杭州: 2011.
[12] Wang B, Zhang S, Yue K, et al. The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases[J]. Chin J Cancer, 2013,32(11):614
[13] Li X, Di B, Shang Y, et al. Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas[J]. Eur J Surg Oncol, 2009,35(12):1348
[14] Lim J Y, Lim Y C, Kim S H, et al. Predictive factors of isolated distant metastasis after primary definitive surgery without systemic treatment for head and neck squamous cell carcinoma[J]. Oral Oncol, 2010,46(7):504
[15] Capote A, Escorial V, Munoz-Guerra M F, et al. Elective neck dissection in early-stage oral squamous cell carcinoma--does it influence recurrence and survival?[J]. Head Neck, 2007,29(1):3

相似文献/References:

[1]王希梅 综述,肖春花 审校.TILs预测不同分子分型乳腺癌新辅助化疗疗效的研究进展[J].天津医科大学学报,2018,24(01):91.

备注/Memo

备注/Memo:

作者简介 刘晓楠(1988-)，女,硕士在读，研究方向：头颈部肿瘤；

通信作者： 张文超， E-mail: zwbeyond_999@sina.com.

更新日期/Last Update: 2015-09-22